| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2016: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2015: ¥780,000 (Direct Cost: ¥600,000、Indirect Cost: ¥180,000)
Fiscal Year 2014: ¥3,250,000 (Direct Cost: ¥2,500,000、Indirect Cost: ¥750,000)
|
|---|
| Outline of Final Research Achievements |
MDA-MB-231 is an estrogen receptor (ER)-negative breast cancer cell line. In contrast to the mitogenic effects of 17beta-estradiol (E2) in ER-positive MCF7, E2 suppresses proliferation of MDA-MB-231 stably transfected with ERalpha cDNA (MDA-ER). In MDA-ER, the BCAR3 and FOSL1 gene expressions were found to be suppressed by the treatment with E2. Because the knock-down of those gene expressions using RNA interference caused the inhibition of the proliferation of MDA-ER treated with vehicle, we hypothesized that the suppression of those gene expressions may be involved in the anti-mitogenic effects of E2. The overexpression of those genes, however, had no effect on the anti-mitogenic effects of E2. These results indicate that E2-induced down regulation of BCAR3 or FOSL1 gene expression does not play a key role for the anti-mitogenic effects of E2.
|
